Miki Ishida
Hachioji, 1920392, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation.
Journal: Scientific reports
Published: October 31, 2024
Hypomyelination Leukodystrophy 16 (HLD16)-Associated Mutation p.Asp252Asn of TMEM106B Blunts Cell Morphological Differentiation.
Journal: Current issues in molecular biology
Published: May 22, 2024
Autism Spectrum Disorder- and/or Intellectual Disability-Associated Semaphorin-5A Exploits the Mechanism by Which Dock5 Signalosome Molecules Control Cell Shape.
Journal: Current issues in molecular biology
Published: February 12, 2024
Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Neurology and therapy
Published: April 11, 2023
Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
Journal: Journal of pain research
Published: October 26, 2022
Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.
Journal: Journal of pain research
Published: October 21, 2022
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.
Journal: The journal of headache and pain
Published: December 05, 2021
Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Journal: Drug safety
Published: August 31, 2021
Showing 1-12 of 12
Last Updated: 09/26/2026